Ken Masuda

2.6k total citations
79 papers, 1.9k citations indexed

About

Ken Masuda is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ken Masuda has authored 79 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 45 papers in Pulmonary and Respiratory Medicine and 14 papers in Molecular Biology. Recurrent topics in Ken Masuda's work include Lung Cancer Treatments and Mutations (37 papers), Cancer Immunotherapy and Biomarkers (25 papers) and Lung Cancer Research Studies (13 papers). Ken Masuda is often cited by papers focused on Lung Cancer Treatments and Mutations (37 papers), Cancer Immunotherapy and Biomarkers (25 papers) and Lung Cancer Research Studies (13 papers). Ken Masuda collaborates with scholars based in Japan, United States and United Kingdom. Ken Masuda's co-authors include Yataro Daigo, Eiju Tsuchiya, Gouji Toyokawa, Hyun‐Soo Cho, Helen I. Field, Bruce A.J. Ponder, Ryuji Hamamoto, Yusuke Nakamura, Nobuoki Kohno and Atsushi Takano and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ken Masuda

74 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ken Masuda Japan 20 931 716 487 266 242 79 1.9k
Edwin J. Ostrin United States 24 1.3k 1.4× 586 0.8× 586 1.2× 559 2.1× 447 1.8× 53 2.3k
Audrey Kauffmann Switzerland 14 895 1.0× 360 0.5× 397 0.8× 227 0.9× 311 1.3× 24 1.8k
Devarati Mitra United States 18 659 0.7× 557 0.8× 247 0.5× 200 0.8× 119 0.5× 53 1.4k
Takefumi Komiya United States 21 599 0.6× 999 1.4× 505 1.0× 127 0.5× 187 0.8× 95 1.8k
Stuart Horswell United Kingdom 23 1.3k 1.4× 525 0.7× 307 0.6× 270 1.0× 620 2.6× 40 2.4k
Craig April United States 22 949 1.0× 246 0.3× 274 0.6× 224 0.8× 506 2.1× 41 1.8k
Hua Mao United States 21 994 1.1× 529 0.7× 128 0.3× 213 0.8× 285 1.2× 52 1.8k
Alberto Benguría Spain 20 1.8k 1.9× 542 0.8× 154 0.3× 381 1.4× 352 1.5× 58 3.1k
Andrew C. Hsieh United States 23 2.6k 2.8× 568 0.8× 423 0.9× 271 1.0× 553 2.3× 70 3.6k

Countries citing papers authored by Ken Masuda

Since Specialization
Citations

This map shows the geographic impact of Ken Masuda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Masuda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Masuda more than expected).

Fields of papers citing papers by Ken Masuda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken Masuda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Masuda. The network helps show where Ken Masuda may publish in the future.

Co-authorship network of co-authors of Ken Masuda

This figure shows the co-authorship network connecting the top 25 collaborators of Ken Masuda. A scholar is included among the top collaborators of Ken Masuda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken Masuda. Ken Masuda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Takeyasu, Yuki, Tsutomu Yoshida, Akio Tateishi, et al.. (2024). Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC. SHILAP Revista de lepidopterología. 5. 100058–100058. 3 indexed citations
3.
Yoshida, Tatsuya, Jumpei Kashima, Masayuki Shirasawa, et al.. (2024). Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression. Lung Cancer. 191. 107788–107788.
4.
Tanaka, Tomohiro, Yasushi Goto, Ken Masuda, et al.. (2024). The remarkable antitumor efficacy of corticosteroid treatment in patients with refractory thymomas. Respiratory Investigation. 62(5). 766–772. 1 indexed citations
5.
Hamai, Kosuke, Sayaka Ueno, Ken Masuda, et al.. (2023). Comprehensive genomic profiling of Japanese patients with thoracic malignancies: A single-center retrospective study. Respiratory Investigation. 61(6). 746–754. 3 indexed citations
6.
Matsumoto, Yuji, Jumpei Kashima, Tatsuya Imabayashi, et al.. (2023). Concordance between cryobiopsy and forceps biopsy specimens in assessment of immunohistochemistry staining for non-small cell lung carcinoma. Translational Lung Cancer Research. 12(6). 1245–1255. 4 indexed citations
7.
Yagishita, Shigehiro, Yoshiharu Hayashi, Yuki Takeyasu, et al.. (2023). Impact of ramucirumab pharmacokinetics in combination with docetaxel on the efficacy and survival in patients with advanced non-small cell lung cancer. Lung Cancer. 178. 247–253. 1 indexed citations
8.
Tanaka, Tomohiro, Yasushi Goto, Masafumi Horie, et al.. (2023). Whole Exome Sequencing of Thymoma Patients Exhibiting Exceptional Responses to Pemetrexed Monotherapy. Cancers. 15(16). 4018–4018. 2 indexed citations
9.
Shibaki, Ryota, Tatsuya Yoshida, Shuji Murakami, et al.. (2022). Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients. Clinical Lung Cancer. 23(6). 477–486. 13 indexed citations
10.
Shinno, Yuki, Akihiko Yoshida, Ken Masuda, et al.. (2022). Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor. Clinical Lung Cancer. 23(5). 386–392. 33 indexed citations
11.
Yoshida, Tatsuya, Takashi Kohno, Ken Masuda, et al.. (2022). Liquid biopsy for the detection of resistance mutations to ROS1 and RET inhibitors in non-small lung cancers: A case series study. Respiratory Investigation. 60(6). 852–856. 2 indexed citations
12.
Tanaka, Tomohiro, Tatsuya Yoshida, Ken Masuda, et al.. (2022). Prognostic role of modified Glasgow Prognostic score in elderly non-small cell lung cancer patients treated with anti-PD-1 antibodies. Respiratory Investigation. 61(1). 74–81. 13 indexed citations
13.
Horinouchi, Hidehito, Ken Masuda, Yuki Shinno, et al.. (2021). Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression. Cancer Immunology Immunotherapy. 71(3). 737–746. 6 indexed citations
14.
Horinouchi, Hidehito, Tatsuya Yoshida, Ken Masuda, et al.. (2021). Correlation between body mass index and efficacy of anti-PD-1 inhibitor in patients with non-small cell lung cancer. Respiratory Investigation. 60(2). 234–240. 10 indexed citations
15.
16.
Goto, Yasushi, Sayaka Arakawa, Masayuki Shirasawa, et al.. (2021). Performance of Japanese patients in registrational studies. Japanese Journal of Clinical Oncology. 52(1). 53–64.
17.
Masuda, Ken, Hidehito Horinouchi, Midori Tanaka, et al.. (2020). Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression. Journal of Cancer Research and Clinical Oncology. 147(1). 245–251. 53 indexed citations
18.
Masuda, Ken, Atsushi Takano, Hirohiko Akiyama, et al.. (2011). Chondrolectin Is a Novel Diagnostic Biomarker and a Therapeutic Target for Lung Cancer. Clinical Cancer Research. 17(24). 7712–7722. 21 indexed citations
19.
Sato, Nagato, Takumi Yamabuki, Atsushi Takano, et al.. (2010). Wnt Inhibitor Dickkopf-1 as a Target for Passive Cancer Immunotherapy. Cancer Research. 70(13). 5326–5336. 129 indexed citations
20.
Takano, Atsushi, Nobuhisa Ishikawa, Ryohei Nishino, et al.. (2009). Identification of Nectin-4 Oncoprotein as a Diagnostic and Therapeutic Target for Lung Cancer. Cancer Research. 69(16). 6694–6703. 211 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Edwin J. Ostrin Breakdown of academic impact, for papers by Audrey Kauffmann Breakdown of academic impact, for papers by Devarati Mitra Breakdown of academic impact, for papers by Takefumi Komiya Breakdown of academic impact, for papers by Stuart Horswell Breakdown of academic impact, for papers by Craig April Breakdown of academic impact, for papers by Hua Mao Breakdown of academic impact, for papers by Alberto Benguría Breakdown of academic impact, for papers by Andrew C. Hsieh
Rankless by CCL
2026